Evidence-Based Cannabis for Dementia-Related Behavioral Agitation
A meta-analysis of 10 RCTs shows medical cannabis can reduce dementia-related agitation—a behavioral symptom that devastates both patients and caregivers. Cannabinoids showed effectiveness comparable to antipsychotics but with a safer profile, especially…
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
Neuropsychiatric symptoms (NPS) are highly prevalent in persons with dementia and have been associated with adverse health outcomes. Neuropsychiatric symptom...
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer's patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s Agitation—But Proof of Efficacy Still Awaited
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer's dementia patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy…
Assessment of Clinical Factors Predicting Nabilone Response for Agitation in Alzheimer’s
This study investigates nabilone response predictors in treating agitation in Alzheimer's disease. Researchers analyzed clinical factors influencing treatment outcomes. Understanding these predictors may guide personalized cannabinoid therapy for…
